|
[1]
|
Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy[J]. Clin Cancer Res, 2011, 17(13): 4550-4557. doi: 10.1158/1078-0432.CCR-11-0116
|
|
[2]
|
Gattinoni L, Powell DJ, Rosenberg SA, et al. Adoptive immunotherapy for cancer: building on success[J]. Nat Rev Immunol, 2006, 6(5): 383-393. doi: 10.1038/nri1842
|
|
[3]
|
Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report[J]. N Engl J Med, 1988, 319(25): 1676-1680. doi: 10.1056/NEJM198812223192527
|
|
[4]
|
Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma[J]. Curr Opin Immunol, 2009, 21 (2): 233-240. doi: 10.1016/j.coi.2009.03.002
|
|
[5]
|
Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know[J]. Nat Rev Clin Oncol, 2011, 8 (10): 577-585. doi: 10.1038/nrclinonc.2011.116
|
|
[6]
|
Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens[J]. J Clin Oncol, 2008, 26(32): 5233-5239. doi: 10.1200/JCO.2008.16.5449
|
|
[7]
|
Paulos CM, Wrzesinski C, Kaiser A, et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8 + T cells via TLR4 signaling[J]. J Clin Invest, 2007, 117(8): 2197-2204. doi: 10.1172/JCI32205
|
|
[8]
|
Weber J, Atkins M, Hwu P, et al. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy[J]. Clin Cancer Res, 2011, 17 (7): 1664-1673. doi: 10.1158/1078-0432.CCR-10-2272
|
|
[9]
|
Rubinstein MP, Kadima AN, Salem ML, et al. Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity[J]. J Immunol, 2003, 170(3): 1209-1217. doi: 10.4049/jimmunol.170.3.1209
|
|
[10]
|
Renkvist N, Castelli C, Robbins PF, et al. A listing of human tumor antigens recognized by T cells[J]. Cancer Immunol Immunother, 2001, 50(1): 3-15. doi: 10.1007/s002620000169
|
|
[11]
|
Clay TM, Custer MC, Sachs J, et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity[J]. J Immunol, 1999, 163(1): 507-513. http://www.researchgate.net/profile/Timothy_Clay2/publication/12915357_Clay_TM_Custer_MC_Sachs_J_Hwu_P_Rosenberg_SA_Nishimura_MIEfficient_transfer_of_a_tumor_antigen-reactive_TCR_to_human_peripheral_blood_lymphocytes_confers_anti-tumor_reactivity_J_Immunol_163_507-513/links/56d74a7508aee73df6c30d45.pdf
|
|
[12]
|
Kieback E, Uckert W. Enhanced T cell receptor gene therapy for cancer [J]. Expert Opin Biol Ther, 2010, 10(5): 749-762. doi: 10.1517/14712591003689998
|
|
[13]
|
Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes[J]. Science, 2006, 314(5796): 126-129. doi: 10.1126/science.1129003
|
|
[14]
|
Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1[J]. J Clin Oncol, 2011, 29(7): 917-924. doi: 10.1200/JCO.2010.32.2537
|
|
[15]
|
Scanlan MJ, Gure AO, Jungbluth AA, et al. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy[J]. Immunol Rev, 2002, 188: 22-32. doi: 10.1034/j.1600-065X.2002.18803.x
|
|
[16]
|
Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity[J]. Proc Natl Acad Sci U S A, 1989, 86(24): 10024-10028. doi: 10.1073/pnas.86.24.10024
|
|
[17]
|
Ramos CA, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy[J]. Expert Opin Biol Ther, 2011, 11(7): 855-873. doi: 10.1517/14712598.2011.573476
|
|
[18]
|
Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia[J]. N Engl J Med, 2011, 365(8): 725-733. doi: 10.1056/NEJMoa1103849
|
|
[19]
|
Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia[J]. Sci Transl Med, 2011, 3(95): 95ra73. http://europepmc.org/articles/PMC3393096/
|
|
[20]
|
Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma[J]. Nat Med, 2008, 14(11): 1264-1270. doi: 10.1038/nm.1882
|
|
[21]
|
Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience[J]. J Clin Oncol, 2006, 24(13): e20-e22. doi: 10.1200/JCO.2006.05.9964
|
|
[22]
|
Chinnasamy D, Yu Z, Theoret MR, et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice[J]. J Clin Invest, 2010, 120(11): 3953-3968. doi: 10.1172/JCI43490
|
|
[23]
|
Pedrazzoli P, Comoli P, Montagna D, et al. Is adoptive T-cell therapy for solid tumors coming of age[J]? Bone Marrow Transplant, 2011, [Epub ahead of print].
|
|
[24]
|
Chiriva-Internati M, Liu Y, Weidanz JA, et al. Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24[J]. Blood, 2003, 102(9): 3100-3107. doi: 10.1182/blood-2002-11-3580
|
|
[25]
|
Liu Y, Chiriva-Internati M, Grizzi F, et al. Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector[J]. Cancer Gene Ther, 2001, 8(12): 948-957. doi: 10.1038/sj.cgt.7700391
|
点击查看大图
下载:
